Table 1.

Summary of SNPs identified in patient-derived integration sites^a

SNP status	Sample	Chromosome location of integration site	GenBank no.	SNPs	No. of clones sequenced
SNPs present, informative	VP432	1; 204400002	EU981801	rs11075704 (C/T), rs72789205 (A/G)	8
	VP363	16; 69090908	EU981808b	rs9661807 (A/G), rs9660554 (A/G)	11
SNPs present, noninformative	VP432	6; 111278735	EU981800	rs6902336 (A/G), rs9487562 (C/G)	8
No SNPs present, noninformative	VP268	11; 72504631	EU981802		8
	VP283	3; 197122283	EU981803		6
	VP283	19; 11254762	EU981804		8
	VP338	12; 46824702	EU981805		7
	VP433	15; 65283282	EU981806		8
	VP234	17; 58591644	EU981807		8
	VP433	14; 31733396	EU981809		6
	VP268	16; 68121168	EU981810b		6
	VP268	7; 28723080	EU981811		6
	VP29	3; 73200877	EU981812		6
	VP229	16; 67973893	EU981813		6

^aIntegration sites are designated by patient identification numbers, chromosome locations, and GenBank accession numbers. Chromosome locations were mapped to the human genome build hg19 and are represented by the chromosome numbers followed by the nucleotide positions. Additional characteristics of the integration site can be found in reference 5. Identified SNPs are indicated by the RefSNP accession numbers, followed by known allele nucleotides in parentheses. To resolve heterozygosity, a minimum of six clones per sample were sequenced.

^bEU981808 and EU981810 are identical to integration sites GU816103 and EU981678, respectively, from experimentally infected DU145 cells (3, 5, 6).